Publications by authors named "S H Cheeseman"
Article Synopsis
- The study aimed to analyze attrition rates from first-line to third-line therapies in patients with HER2-positive metastatic breast cancer across several European countries.
- It found that 29.6% of patients discontinued treatment after first-line therapy and 34.2% after second-line therapy, often due to death or transition to palliative care.
- Additionally, the time patients remained on treatment decreased with each line of therapy, indicating diminishing effectiveness of subsequent treatments.
Background: Poly(ADP-ribose) polymerase inhibitors (PARPis) improved advanced ovarian cancer treatment. Most patients progress during or following PARPi exposure, however, with concerns about sensitivity of subsequent chemotherapy.
Patients And Methods: In this international cohort study, we evaluated the efficacy of a subsequent chemotherapy following PARPi exposure in high-grade ovarian carcinoma patients.
Article Synopsis
- * Scientists are using new technology called nanotechnology to study these channels better and even create synthetic ones that can be used for medicine.
- * The review discusses both the cool ways nanotechnology helps us understand ion channels and the challenges we might face in using these new methods in the future.
This study aimed to develop and evaluate the performance of algorithms for identifying radiotherapy (RT) treatment intent in real-world data from patients with non-metastatic non-small-cell lung cancer (NSCLC). Using data from IPO-Porto hospital (Portugal) and the REAL-Oncology database (England), three algorithms were developed based on available RT information (#1: RT duration, #2: RT duration and type, #3: RT dose) and tested versus reference datasets. Study results showed that all three algorithms had good overall accuracy (91-100%) for patients receiving RT plus systemic anticancer therapy (SACT) and algorithms #2 and #3 also had good accuracy (>99%) for patients receiving RT alone.
View Article and Find Full Text PDFAntibiotics are compounds that have a particular mode of action upon the microorganism they are targeting. However, discovering and developing new antibiotics is a challenging and timely process. Antibiotic development process can take up to 10-15 years and over $1billion to develop a single new therapeutic product.
View Article and Find Full Text PDF